Back to top
Top

Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy

Measure Information 2023 Performance Period
CMS eCQM ID CMS645v6
NQF Number Not Applicable
Description

Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.

Initial Population

Male patients with a qualifying encounter in the measurement period AND with a diagnosis of prostate cancer AND with an order for ADT or an active medication of ADT with an intent for treatment greater than or equal to 12 months during the measurement period

Denominator

Equals Initial Population

Denominator Exclusions

None

Numerator

Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment

Numerator Exclusions

Not Applicable

Denominator Exceptions

Patient refused the bone density evaluation at the time ordered or did not have it performed within 3 months after the start of ADT

Measure Steward Oregon Urology
Quality Domain Effective Clinical Care
Measure Scoring Proportion measure
Measure Type Process measure
Improvement Notation

A higher score indicates better quality

Guidance

In order to capture the practitioner's intent of androgen deprivation therapy (ADT) for a period of 12 months or greater, SNOMEDCT 456381000124102 which is Injection of leuprolide acetate for twelve month period (regime/therapy) is the correct code.

This eCQM is a patient-based measure.

This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.

MIPS Quality ID 462
Meaningful Measure Management of Chronic Conditions
Telehealth Eligible Yes
Next Version No Version Available
Previous Version

Compare eCQM Versions

The Compare function compares two years of the measure specifications found in the header of the measure's HTML. It does not include a comparison of any information in the body of the HTML, e.g., population criteria, Clinical Quality Language, or value sets.

Strikethrough text highlighted in red indicates information changed from the previous version. Text highlighted in green indicates information updated in the new eCQM version.

Filter Measure By
Download
Measure Information 2021 Performance Period 2022 Performance Period 2023 Performance Period
Title Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy
CMS eCQM ID CMS645v4 CMS645v5 CMS645v6
NQF Number Not Applicable Not Applicable Not Applicable
Description

Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.

Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.

Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.

Initial Population

Male patients with a qualifying encounter in the measurement period AND with a diagnosis of prostate cancer AND with an order for ADT or an active medication of ADT with an intent for treatment greater than or equal to 12 months during the measurement period

Male patients with a qualifying encounter in the measurement period AND with a diagnosis of prostate cancer AND with an order for ADT or an active medication of ADT with an intent for treatment greater than or equal to 12 months during the measurement period

Male patients with a qualifying encounter in the measurement period AND with a diagnosis of prostate cancer AND with an order for ADT or an active medication of ADT with an intent for treatment greater than or equal to 12 months during the measurement period

Denominator

Equals Initial Population

Equals Initial Population

Equals Initial Population

Denominator Exclusions None None None
Numerator

Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment

Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment

Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment

Numerator Exclusions

Not Applicable

Not Applicable

Not Applicable

Denominator Exceptions

Patient refused recommendation for a bone density evaluation after the start of ADT therapy

Patient refused recommendation for a bone density evaluation after the start of ADT therapy

Patient refused the bone density evaluation at the time ordered or did not have it performed within 3 months after the start of ADT

Measure Steward Oregon Urology Oregon Urology Oregon Urology
Quality Domain Effective Clinical Care Effective Clinical Care Effective Clinical Care
Measure Scoring Proportion measure Proportion measure Proportion measure
Measure Type Process measure Process measure Process measure
Improvement Notation

A higher score indicates better quality

A higher score indicates better quality

A higher score indicates better quality

Guidance

In order to capture the practitioner's intent of androgen deprivation therapy (ADT) for a period of 12 months or greater, SNOMEDCT 456381000124102 which is Injection of leuprolide acetate for twelve month period (regime/therapy) is the correct code.

This eCQM is a patient-based measure.

This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center for more information on the QDM.

In order to capture the practitioner's intent of androgen deprivation therapy (ADT) for a period of 12 months or greater, SNOMEDCT 456381000124102 which is Injection of leuprolide acetate for twelve month period (regime/therapy) is the correct code.

This eCQM is a patient-based measure.

This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center (https://ecqi.healthit.gov/qdm) for more information on the QDM.

In order to capture the practitioner's intent of androgen deprivation therapy (ADT) for a period of 12 months or greater, SNOMEDCT 456381000124102 which is Injection of leuprolide acetate for twelve month period (regime/therapy) is the correct code.

This eCQM is a patient-based measure.

This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.

MIPS Quality ID 462 462 462
Meaningful Measure Management of Chronic Conditions Management of Chronic Conditions Management of Chronic Conditions
Telehealth Eligible Yes Yes Yes
Next Version CMS645v5 CMS645v6 No Version Available
Previous Version No Version Available

Release Notes

Header

  • Updated copyright.

    Measure Section: Copyright

    Source of Change: Annual Update

  • Removed reference to a value set within the definition to point to the terminology section as the source of truth.

    Measure Section: Definition

    Source of Change: Measure Lead

  • Updated grammar and formatting to improve readability.

    Measure Section: Definition

    Source of Change: Measure Lead

  • Revised grammar in reference to First Androgen Deprivation Therapy.

    Measure Section: Definition

    Source of Change: Measure Lead

  • Updated version number of the Quality Data Model (QDM) used in the measure specification to v5.6.

    Measure Section: Guidance

    Source of Change: Standards/Technical Update

  • Revised the narrative to better align with the logic.

    Measure Section: Denominator Exceptions

    Source of Change: Measure Lead

Logic

  • Added definition 'First ADT During Measurement Period and Order for 12 Months of ADT During Measurement Period' to correctly capture the initial population, and properly anchor the first ADT and the order for intended 12 months of treatment.

    Measure Section: Definitions

    Source of Change: Measure Lead

  • Replaced definition 'Androgen Deprivation Therapy Start Date With Prostate Cancer And Intended 12 Months Therapy' definition and logic to accurately capture measure intent of linking the ADT, prostate cancer diagnosis, and the provider's intention to continue treatment for 12 months.

    Measure Section: Definitions

    Source of Change: Measure Lead

  • Revised the timing in the 'Prostate Cancer Diagnosis' definition by replacing the timing of 'same day or before end' with 'overlaps' to anchor the timing of prostate cancer to the measurement period.

    Measure Section: Definitions

    Source of Change: ONC Project Tracking System (JIRA): CQM-4761

  • Updated the names of CQL definitions, functions, and/or aliases for clarification and to align with the CQL Style Guide.

    Measure Section: Multiple Sections

    Source of Change: Standards/Technical Update

  • Updated the version number of the Measure Authoring Tool (MAT) Global Common Functions Library to v7.0.000.

    Measure Section: Multiple Sections

    Source of Change: Standards/Technical Update

  • Updated the version of the Quality Data Model (QDM) to 5.6 and Clinical Quality Language (CQL) to 1.5.

    Measure Section: Multiple Sections

    Source of Change: Standards/Technical Update

Value set

The VSAC is the source of truth for the value set content, please visit the VSAC for downloads of current value sets.

  • Replaced value set Patient Declined (2.16.840.1.113883.3.600.791) with value set Patient Declined (2.16.840.1.113883.3.526.3.1582) based on new or changed coding guidelines.

    Measure Section: Terminology

    Source of Change: Annual Update

Last Updated: Aug 29, 2022